Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 7Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Chronic 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1GATA2 Deficiency 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

Rituximab 23Cyclophosphamide 21Prednisone 16Doxorubicin 14Magnetic Resonance Spectroscopy 13Vincristine 11Specimen Handling 11Lenalidomide 10ibrutinib 8Biopsy 8obinutuzumab 7polatuzumab vedotin 6glofitamab 6Gemcitabine 6Oxaliplatin 5venetoclax 4prednylidene 4pembrolizumab 4fludarabine 4deltacortene 4Prednisolone 4Etoposide 4Dexamethasone 4Cyclosporine 4CT-P10 4fludarabine phosphate 3Whole-Body Irradiation 3R-CHOP protocol 3Nivolumab 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × decitabine and cedazuridine drug combination × 30 days × Clear all
NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Recruiting
32 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡